Skip to main content

Table 2 Subject characteristics for real-time PCR

From: Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy

 

T1 ≥ 470

T1 < 470

n

28

27

Gender (m/f)

22/6

22/5

Age (years)

49.1 ± 14.0

49.9 ± 10.8

Height (cm)

171.3 ± 10.7

174.9 ± 7.9

Weight (kg)

81.8 ± 18.7

88.5 ± 14.7

Body mass index (kg/m2)

27.6 ± 4.5

28.9 ± 4.0

Family history of HCM (%)

35.7 %

11.1 %*

Resting heart beat (beats/min)

63.9 ± 10.5

61.5 ± 16.1

Systolic blood pressure (mmHg)

129.7 ± 17.3

130.8 ± 14.9

Diastolic blood pressure (mmHg)

75.0 ± 9.1

71.6 ± 8.6

eGFR (mL/min/1.75 m2)

83.9 ± 7.6

79.7 ± 13.8

Medications

 β-blockers

50 %

63 %

 Calcium channel blockers

14.3 %

29.6 %

 Angiotensin convert enzyme inhibitor

10.7 %

22.2 %

 Angiotensin receptor blockers

21.4 %

3.7 %

Echocardiography

 Left atrial volume indexed, ml/m2

48.4 ± 18.2

49.6 ± 13.9

 E/A ratio

1.35 ± 0.63

1.40 ± 0.67

 Deceleration time (ms)

200.0 ± 64.0

226.4 ± 44.0

 Septal e′ (cm/s)

6.5 ± 1.5

5.9 ± 1.7

 Lateral e′ (cm/s)

8.5 ± 1.9

7.6 ± 2.9

 Mean e′ (cm/s)

7.5 ± 1.4

6.7 ± 2.1

 Septal E/e′

12.5 ± 3.8

14.8 ± 5.9

 Lateral E/e′

9.8 ± 3.8

12.0 ± 5.1

 Mean E/e′

11.0 ± 3.4

13.4 ± 5.1

 Resting LVOT gradient (mmHg)

32.8 ± 39.6

49.9 ± 51.0

CMR

 T1 times (ms), excluding LGE

536.3 ± 54.6

441.0 ± 30.0***

 T1 times (ms), including LGE

521.3 ± 66.4

432.3 ± 26.2***

 T1 times (ms, corrected values)

518.7 ± 55.2

423.8 ± 34.1***

 Blood T1 times (ms)

310.7 ± 30.4

296.0 ± 29.3

 Septal thickness (mm)

20.3 ± 5.8

19.1 ± 3.3

 Lateral wall thickness (mm)

8.6 ± 1.8

9.2 ± 1.9

 Septal/lateral wall thickness

2.4 ± 0.7

2.1 ± 0.5

 LV mass index (g/BSA)

92.6 ± 35.0

87.4 ± 22.4

 LV ejection fraction (%)

68.5 ± 7.3

70.8 ± 6.5

 Presence of LGE (%)

85.7 %

81.5 %

 Quantity of LGE (% of LV) mass

5.6 ± 7.5

4.7 ± 6.1

  1. Data are expressed as mean ± SD
  2. CMR cardiac magnetic resonance, LV left ventricular, LVOT left ventricular outflow tract, LGE late gadolinium enhancement, BSA body surface area, T1 times (corrected values): T1 times were normalized to a matched state (time post-contrast administration = 20 min, eGFR = 90 mL/min/1.73 m2) to account for the potential effects of glomerular filtration rate, time delay post-contrast administration, and contrast agent relaxivity on gadolinium pharmacokinetics
  3. * P < 0.05, *** P < 0.001, vs. T1 ≥ 470 ms